Abstract
Objectives: To identify the impact of Lipocalin-2 (LCN2) gene polymorphisms on breast cancer patients in Jeddah, Saudi Arabia.
Methods: It is a case control study in which blood samples of participants from Medical Reference Clinics and King Abdulaziz University Hospital in Jeddah, Saudi Arabia have been taken between 2014 and 2016. This study recruited 128 participants (50% control, 50% patients) and used Tetra-Primer amplification-refractory mutation system-polymerase chain reaction method for the detection of missense SNP (rs11556770). The study measured LCN2 plasma protein expression by enzyme-linked immunosorbent assay technique.
Results: The results have shown that 100% of the genotypes were normal allele (G/G). In contrast, the Original Articles plasma level of LCN2 was considerably elevated among patients as compared to control (p=0.001), and higher in invasive ductal carcinoma patients (p=0.001). The LCN2 protein expression in plasma level was significantly elevated among patients, particularly who demonstrated invasive ductal carcinoma.
Conclusion: There is no significant relationship between breast cancer patients and LCN2 gene polymorphisms (rs11556770).